Rod Knight1,2, Perrine Roux3,4, Antoine Vilotitch3,4, Fabienne Marcellin3,4, Eric Rosenthal5,6, Laure Esterle7, François Boué8,9, David Rey10, Lionel Piroth11, Stéphanie Dominguez12, Philippe Sogni13,14,15, Dominique Salmon-Ceron15,16, Bruno Spire3,4, Maria Patrizia Carrieri3,4. 1. Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. 2. School of Population and Public Health, University of British Columbia, Vancouver, Canada. 3. Aix Marseille Université, INSERM, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l'Information Médicale, Marseille, France. 4. ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France. 5. Service de Médecine Interne et Cancérologie, Hôpital l'Archet, Centre Hospitalier Universitaire de Nice, France. 6. Université de Nice-Sophia Antipolis, Nice, France. 7. INSERM, ISPED, Centre INSERM U1219-Bordeaux Population Health, Bordeaux, France. 8. Université Paris Sud, Paris, France. 9. Service Médecine interne et immunologie, AP-HP, Groupe Hospitalier Paris Sud, Hôpital Antoine-Béclère, Clamart, France. 10. Department of Infectious Diseases, Hôpitaux Universitaires, Strasbourg, France. 11. Centre Hospitalier Universitaire Dijon, and Unité Mixte de Recherche 1347, Université de Bourgogne, Dijon, France. 12. Service Immunologie clinique et maladies infectieuses, Immunologie clinique, AP-HP, Hôpital Henri Mondor, Créteil, France. 13. Service d'Hépatologie, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Cochin, Paris, France. 14. INSERM U-1223-Institut Pasteur, Paris, France. 15. Université Paris Descartes, Paris, France. 16. Service Maladies infectieuses et tropicales, AP-HP, Hôpital Cochin, Paris, France.
Abstract
BACKGROUND AND AIMS: Few data exist on changes to substance use patterns before and after hepatitis C virus (HCV) treatment. We used longitudinal data of HIV-HCV co-infected individuals to examine whether receiving pegylated interferon (Peg-IFN)-based therapy irrespective of HCV clearance could modify tobacco, cannabis and alcohol use. DESIGN: A prospective cohort of HIV-HCV co-infected individuals was enrolled from 2006. Participants' clinical data were retrieved from medical records and socio-demographic and behavioural characteristics were collected by yearly self-administered questionnaires. SETTING: Data were collected across 17 hospitals in France. PARTICIPANTS: All HIV-HCV co-infected patients who initiated HCV treatment during follow-up and answered items regarding substance use in at least one yearly questionnaire (258 patients, 671 visits). INTERVENTION: HCV treatment consisted of Peg-IFN-based regimens. MEASUREMENTS: Four time-varying outcomes: hazardous alcohol use (Alcohol Use Disorders Identification Test-C > 3/4 for women/men), number of alcohol units/month, binge drinking, cannabis and tobacco use. Mixed models assessed the effect of HCV treatment status (not yet treated, treated and HCV-cleared, treated and HCV-chronic) on each outcome. FINDINGS: A significant decrease (more than 60% reduction) in both hazardous alcohol use and binge drinking and a reduction of 10 alcohol units/month was observed after HCV treatment (irrespective of HCV clearance). No significant effect of HCV treatment status was found on tobacco use and regular cannabis use, but HCV 'clearers' reported less non-regular use of cannabis. CONCLUSIONS: Hepatitis C virus (HCV) treatment appears to help HIV-HCV co-infected patients reduce alcohol use.
BACKGROUND AND AIMS: Few data exist on changes to substance use patterns before and after hepatitis C virus (HCV) treatment. We used longitudinal data of HIV-HCV co-infected individuals to examine whether receiving pegylated interferon (Peg-IFN)-based therapy irrespective of HCV clearance could modify tobacco, cannabis and alcohol use. DESIGN: A prospective cohort of HIV-HCV co-infected individuals was enrolled from 2006. Participants' clinical data were retrieved from medical records and socio-demographic and behavioural characteristics were collected by yearly self-administered questionnaires. SETTING: Data were collected across 17 hospitals in France. PARTICIPANTS: All HIV-HCV co-infectedpatients who initiated HCV treatment during follow-up and answered items regarding substance use in at least one yearly questionnaire (258 patients, 671 visits). INTERVENTION: HCV treatment consisted of Peg-IFN-based regimens. MEASUREMENTS: Four time-varying outcomes: hazardous alcohol use (Alcohol Use Disorders Identification Test-C > 3/4 for women/men), number of alcohol units/month, binge drinking, cannabis and tobacco use. Mixed models assessed the effect of HCV treatment status (not yet treated, treated and HCV-cleared, treated and HCV-chronic) on each outcome. FINDINGS: A significant decrease (more than 60% reduction) in both hazardous alcohol use and binge drinking and a reduction of 10 alcohol units/month was observed after HCV treatment (irrespective of HCV clearance). No significant effect of HCV treatment status was found on tobacco use and regular cannabis use, but HCV 'clearers' reported less non-regular use of cannabis. CONCLUSIONS:Hepatitis C virus (HCV) treatment appears to help HIV-HCV co-infectedpatients reduce alcohol use.
Authors: Zahid Ahmad Butt; Nabin Shrestha; Stanley Wong; Margot Kuo; Dionne Gesink; Mark Gilbert; Jason Wong; Amanda Yu; Maria Alvarez; Hasina Samji; Jane A Buxton; James C Johnston; Victoria J Cook; David Roth; Theodora Consolacion; Michelle Murti; Travis S Hottes; Gina Ogilvie; Robert Balshaw; Mark W Tyndall; Mel Krajden; Naveed Z Janjua Journal: PLoS One Date: 2017-08-22 Impact factor: 3.240
Authors: Nicole J Kim; Meredith Pearson; Philip Vutien; Feng Su; Andrew M Moon; Kristin Berry; Pamela K Green; Emily C Williams; George N Ioannou Journal: Hepatol Commun Date: 2020-01-02